Physician profile
Stephanie Gan
NPI 1629399654
$2,042.12
in general payments reported to CMS, 2019-2025
14 companies · $505 in 2025
The $505 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2021: $216 · 2022: $270 · 2023: $116 · 2024: $324 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $945.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $925.86 | 2019-2025 | |
| Galderma Laboratories, L.P. | $285.38 | 2022-2025 | Nemluvio |
| Dermavant Sciences, INC. | $232.13 | 2024 | Vtama |
| Genzyme Corporation | $144.98 | 2021 | |
| Janssen Biotech, INC. | $120.33 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $110.07 | 2019 | |
| Amgen INC. | $54.05 | 2025 | Otezla |
| Pfizer INC. | $50.95 | 2023-2024 | |
| Lilly USA, LLC | $23.65 | 2025 | Ebglyss |
| Allergan, INC. | $22.58 | 2021 | |
| Arcutis Biotherapeutics, INC. | $19.85 | 2025 | Zoryve |
| Solta Medical, A Division of Bausch Health US, LLC | $18.77 | 2024 | Clear+Brilliant |
| Merz North America, INC. | $18.30 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.22 | 2025 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Gan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.